Limiting the overall use of antibiotics constitutes a topical challenge for food animal industry. To reach this objective, vaccination plays a critical role by reducing the incidence and severity of high-impact diseases. At present, new alternatives to conventional antibody-based vaccines are necessary for controlling numerous animal diseases. In this context, CelBoVax proposes an innovative approach to produce next-generation vaccines aimed at boosting cattle cell-mediated immunity. As proof-of-concept, we will target Staphylococcus aureus, a major pathogen of dairy cows. By combining multidisciplinary approaches, our efforts will be focused on each step of a prototype vaccine production pipeline including: development and selection of new yeast-based antigen delivery systems, identification of pertinent candidate antigens by state-of-the-art proteomics and in silico analysis and setting up of simple and affordable assays to test the in vivo activity of candidate vaccines.